Macrophage TBK1 signaling drives the development and outgrowth of breast cancer brain metastasis
Abstract
Tumor-associated macrophages (TAMs) are the predominant immune cells in the tumor microenvironment that promote breast cancer brain metastasis (BCBM). Here, we identify TANK-binding kinase (TBK1) as a critical signaling molecule enriched and activated in TAMs of BCBM tumors, playing an indispensable role in BCBM development and metastatic outgrowth in the brain. Mechanistically, BCBM cell-secreted matrix metalloproteinase 1 binds to protease-activated receptor 1 and integrin αVβ5 on macrophages, leading to TBK1 activation mediated by the nuclear factor-kappa B pathway. Reciprocally, TBK1-regulated TAMs produce granulocyte-macrophage colony-stimulating factor (GM-CSF) to drive breast cancer cell epithelial–mesenchymal transition, migration, and invasion, ultimately contributing to BCBM development and brain metastatic outgrowth. Inhibition of TBK1 signaling in TAMs or GM-CSF receptor in cancer cells impedes BCBM development and brain metastatic outgrowth. Correspondingly, the TBK1–GM-CSF signaling axis correlates with lower overall survival in patients with BCBM. Thus, TBK1-mediated tumor-TAM symbiotic interaction provides a promising therapeutic target for patients with BCBM.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (11)
Fatima Khan
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
Yang Liu
Donovan Whitfield
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
Lizhi Pang
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
Heba Ali
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University
Yuyun Huang
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
Fei Zhou
Robert S. Hagan
Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill
Katie Frenis
Department of Hematology, Boston Children’s Hospital
R. Grant Rowe
Department of Hematology, Boston Children’s Hospital
Peiwen Chen
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic